India to tax freebies to physicians; industry fears return of inspector raj
This article was originally published in Scrip
Medical conferences-cum-family vacations at exotic resorts abroad, courtesy of pharmaceutical companies, or the latter sponsoring the higher education of children of "important" physicians may no longer be easy in India. The taxman is watching.
You may also be interested in...
Years after a scathing Indian parliamentary report flagged concerns around regulatory lapses for drug approvals, an expert panel has endorsed the continued marketing of ambrisentan and everolimus in the country. But dronedarone, also featured in the report, is no longer sold by Sanofi in India.
Tecentriq cleared for extensive-stage small cell lung cancer in India but pricing remains a key constraining factor. Patient assistance schemes help but such novel therapies still unaffordable to a vast majority.